IntegenX Names Biotechnology Veteran David V. Smith Chief Operating Officer

Press Releases
Typography

IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA room temperature stability and storage products, today announced the appointment of David V. Smith as Chief Operating Officer.

David V. Smith has more than 30 years of financial and operational management experience, and has held leadership positions in the biotechnology industry for more than two decades. Most recently, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, a company he joined in 1999. At Chiron, he held a number of increasingly responsible positions including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Prior to Chiron, Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation.

“Of all the advances in life science technology, the integration of complex chemistry and biology systems is now made possible by the practical utilization of microfluidics technology. The resulting sample-to-answer solutions are revolutionizing medical care, medical discovery and other applications that affect our health and safety,” said Mr. Smith. “I am particularly excited to join IntegenX just as the company prepares to launch the first microfluidics-based rapid DNA human identification system for the law enforcement, defense, forensics and security markets.”

Mr. Smith is currently chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc. and was previously chair of the Audit Committee and a Director of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.

Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX commented: “David has been part of the executive leadership and management of the biotechnology industry since its inception in the 1980s, including working within large public companies operating in highly regulated markets. Having played a key role in pioneering companies such as Genentech, Chiron, and Thoratec, we are proud to have him join us at this exciting phase of growth at IntegenX as we lead the establishment of the emerging rapid DNA identification industry.”

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, Next-Gen Sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.